Kintara Therapeutics, Inc.
KTRA
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.28M | 1.49M | 908.00K | 1.10M | 1.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.39M | 2.09M | 1.02M | 2.96M | 3.35M |
| Operating Income | -2.39M | -2.09M | -1.02M | -2.96M | -3.35M |
| Income Before Tax | -2.32M | -2.01M | -1.02M | -2.96M | -3.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.32M | -2.01M | -1.02M | -2.96M | -3.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.32M | -2.01M | -1.02M | -2.96M | -3.34M |
| EBIT | -2.39M | -2.09M | -1.02M | -2.96M | -3.35M |
| EBITDA | -2.37M | -2.08M | -1.00M | -2.95M | -3.33M |
| EPS Basic | -1.48 | -1.58 | -8.27 | -63.91 | -69.03 |
| Normalized Basic EPS | -0.92 | -0.99 | -5.16 | -37.71 | -43.12 |
| EPS Diluted | -1.48 | -1.58 | -8.27 | -63.91 | -69.03 |
| Normalized Diluted EPS | -0.92 | -0.99 | -5.16 | -37.71 | -43.12 |
| Average Basic Shares Outstanding | 1.57M | 1.27M | 123.90K | 49.10K | 48.30K |
| Average Diluted Shares Outstanding | 1.57M | 1.27M | 123.90K | 49.10K | 48.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.00% | -0.10% | -0.20% | -0.07% | -0.06% |
